Clearthesis
Sign inSign up

Sign up free to access investment thesis for 500+ leading US stocks

AppleAppleMicrosoftMicrosoftNvidiaNvidiaAmazonAmazonAlphabetAlphabetMetaMetaTeslaTeslaBroadcomBroadcomAMDAMDTSMCTSMCArmArmQualcommQualcommMicronMicronMarvellMarvellOracleOracleAdobeAdobeSalesforceSalesforceServiceNowServiceNowCrowdStrikeCrowdStrikePalo AltoPalo AltoSpotifySpotifyCloudflareCloudflareShopifyShopifyVisaVisaMastercardMastercardRobinhoodRobinhoodCoinbaseCoinbasePalantirPalantirBerkshireBerkshireCostcoCostcoWalmartWalmartNetflixNetflixJPMorganJPMorgan
View all covered stocks →
Clearthesis
PrivacyTermsContact

© 2026 ClearThesis, Inc.

For informational purposes only. Not investment advice. ClearThesis is not a registered investment adviser.

CE

CelaneseCE

$46.80
Updated Aug 22, 2026
Quality Score
2.4
Follow

Latest Celanese updates

Follow Celanese to never miss an important update.

$46.80
Loading…
CE
ProductPositive
Aug 17

Celanese partners with VIGOR for humanoid robot materials

Celanese is partnering with VIGOR to build a new system for lightweight joints used in humanoid robots. This move targets the growing robotics industry, where reducing weight without losing strength is a major technical challenge.

While this is a small niche today, it shows the company finding new uses for its specialty materials beyond its traditional automotive and industrial customers. Diversifying into high-tech robotics could help protect profits if demand in older sectors like construction slows down.

Source: Business Wire

CE
Insider activityPositive
Aug 14

CFO and other executives buy about $230,000 in stock

Chief Financial Officer Chuck Kyrish and two other senior vice presidents bought a combined $230,000 worth of shares this month. These were open-market purchases, meaning the executives used their own cash to buy stock at current prices rather than just receiving shares as part of their pay.

When multiple top leaders buy shares at the same time, it often suggests they believe the stock is undervalued. Given that the company recently slashed its dividend to pay down debt, these purchases may be a signal from the leadership team that they are confident in the turnaround plan.

CE
Analyst price updateFor the record
Aug 6

Wells Fargo lowered its target to $65

Wells Fargo kept its positive rating but cut its target from $80 to $65. Three other firms, including Deutsche Bank and BMO Capital, also lowered their targets this week, bringing the average analyst target to $60. These changes follow the company's decision to cut its dividend and focus on paying down debt. While analysts still see the stock as worth more than its current $46.80 price, they are tempering their expectations as the company works through a difficult period of high interest costs and heavy debt.

Source: Wells Fargo

CE
EarningsPositive
Aug 4

Earnings beat expectations as prices and volumes rise

Celanese reported a strong second quarter, with profits coming in higher than expected. Sales rose 18 percent compared to the previous three months, driven by a 14 percent jump in prices and a 4 percent increase in the amount of chemicals sold. The company saw particularly strong demand in its medical and electronics businesses.

This result is a good sign for the company's turnaround plan. It shows that Celanese can still raise prices and grow its business even while it is aggressively cutting costs and shutting down older plants to pay off debt. If the company can keep this momentum, it will be in a much better position to handle its large interest payments.

See the full quarter, and how our tracked metrics did

Source: 8-K filing

CE
FilingFor the record
Aug 4

Lenders loosen debt rules to give Celanese more breathing room

Celanese reached an agreement with its lenders to raise the limit on its debt-to-earnings ratio, a rule known as a financial covenant. The new limit starts at 5.5 times its earnings and will gradually step down over time.

This change is a safety net. It gives the company more room to operate without breaking its loan rules while it works to pay down its $10.7 billion debt load. While it doesn't change how much the company owes, it reduces the risk that a temporary dip in profits would trigger a default on its loans.

Source: 8-K filing

Celanese analyst price targets

Analysts recently lowered their price targets following the company's latest earnings report. While 11 of 37 analysts rate the stock a buy, the average target of $60 suggests a 29% upside from the current price.

Average target$60.40+29%vs $46.80 today
TodayAvg price
Low $50High $75
Hold37 analysts
4Bearish
22Neutral
11Bullish
FirmRatingPrice TargetDate
Deutsche Bank
—
$60→$50
8/6/2026
Wells Fargo
Overweight
$80→$65
8/6/2026
Mizuho Securities
Neutral
$55→$50
8/5/2026
BMO Capital
Market Perform
$57→$54
8/5/2026
Deutsche Bank
—
$60
7/22/2026
Morgan Stanley
Equal Weight
$72→$58
7/16/2026
BMO Capital
Market Perform
$80→$57
7/6/2026
RBC Capital
Sector Perform
$66→$68
5/11/2026
RBC Capital
Sector Perform
$55→$66
4/10/2026
Wells Fargo
Overweight
$70→$75
4/10/2026
UBS
Neutral
$58→$64
4/9/2026
Robert W. Baird
Outperform
$65→$75
3/27/2026

Celanese earnings

Management has a history of clearing the bar they set, and a recent big jump in earnings suggests their plan to raise prices is working despite a heavy debt load.

Earnings history
EstimateBeatMiss
$0.31$1.61$2.91Nov '24Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26nextNov '26

Celanese past earnings results

ExpectedActualSurprise
EPS$2.23$2.45+9.9%
Revenue$2.75B$2.75B+0.2%

Key highlights

  • Massive pricing power: The company increased prices by 14% this quarter, which was the main reason sales rose 18% to reach $2.8 billion even as demand for products only grew a little bit. This ability to charge more helped offset higher costs and delivered the best earnings results the company has seen in nearly three years.
  • Acetyl Chain performance jump: Sales in the Acetyl Chain division, which makes chemicals used in everything from paints to solar panels, surged 28% compared to the previous three months to hit $1.33 billion. Prices in this specific part of the business jumped 22% because the company used its global shipping network to fill supply gaps for customers in the Western Hemisphere.
  • Cost savings on track: Management expects to save more than $50 million in annual costs by closing down older factories in South Korea and Belgium and moving that work to more efficient sites in China and India. These moves are part of a plan to make the business more profitable over the long term by spending less on running plants that are no longer competitive.
  • Cash generation slowed: Free cash flow, the money left after paying for all business operations and equipment, fell to $140 million compared to $311 million a year ago. This happened because the company had to tie up more cash in inventory and receivables to support its higher sales volume during the quarter.
  • Mixed outlook ahead: Management expects third quarter earnings of approximately $1.35 to $1.75 per share, which is a step down from the $2.45 earned this quarter as raw material costs rise. Even with that dip, the company is sticking to its full year goal of earning $6.00 per share and generating $700 million to $800 million in free cash flow.

Our take: A very strong quarter that shows this company can raise prices effectively even when the broader economy is uncertain. The huge jump in profit from the Acetyl Chain division is the standout factor, and while the next quarter might be a bit quieter, the long term case for the business is getting stronger as they cut costs and pay down debt.

Celanese’s next earnings date

Q3 2026
NOV
5
Expectation
EPS$1.53
Revenue$2.62B

Metrics we are tracking

Metric
Expectations
Status
Free Cash Flow
Reaching $700 million to $800 million for the full year 2026
$140M in Q2 2026
Adjusted EPS
Maintaining a trend toward $6.00 for the full year 2026
$2.45 in Q2 2026
Net Debt to EBITDA
Falling toward the management target of 4.8x by year-end
~5.0x as of Q2 2026
Pricing Growth
Holding mid-single-digit price increases despite volume weakness
14% in Q2 2026

Stay on top of Celanese

Follow Celanese to get the latest and most important updates.

Follow CE

On this page

Full thesisFollow CE